TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07462143: A Randomized, Multicenter, Phase Ⅱ/Ⅲ Study of RC148 Combined With Chemotherapy Versus Bevacizumab Combined With Chemotherapy as First-line Treatment for Unresectable or Metastatic Colorectal Cancer

Sponsor: RemeGen Co., Ltd. · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$676,368

Rescue Site Savings

+$450,912

Unlock Full NCT07462143 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07462143 Rescue Dossier →